NCT03606460View on ClinicalTrials.gov

A Study to Evaluate the Safety of Administering Ocrelizumab Per a Shorter Infusion Protocol in Participants With Primary Progressive Multiple Sclerosis (PPMS) and Relapsing Multiple Sclerosis (RMS)

PHASE3CompletedINTERVENTIONAL
Enrollment

141

Participants

Timeline

Start Date

September 14, 2018

Primary Completion Date

May 31, 2019

Study Completion Date

May 31, 2019

Conditions
Multiple Sclerosis
Interventions
DRUG

Ocrelizumab Dose 1

300 mg infusion administered to ocrelizumab-naive participants per approved protocol (over approximately 2.5 hours or longer) as per standard of care followed by a second 300 mg shorter infusion over approximately 1.5 hours.

DRUG

Ocrelizumab Dose 2 and Dose 3

600 mg infusion of ocrelizumab administered at a shorter rate (i.e. over the course of approximately 2 hours) at Week 24 and at Week 48

Trial Locations (5)

43215

Ohio Health Research Institute Grant Medical Center, Columbus

44195

Cleveland Clinic Fndn, Cleveland

73104

Oklahoma Medical Research Foundation; MS Center of Excellence, Oklahoma City

80045

University of Colorado; Anschutz Medical Campus Department of Neurology, Aurora

02481

Dragonfly Research, LLC, Wellesley

Sponsors

Lead Sponsor

Genentech, Inc.
All Listed Sponsors
lead

Genentech, Inc.

INDUSTRY

NCT03606460 - A Study to Evaluate the Safety of Administering Ocrelizumab Per a Shorter Infusion Protocol in Participants With Primary Progressive Multiple Sclerosis (PPMS) and Relapsing Multiple Sclerosis (RMS) | Biotech Hunter | Biotech Hunter